- Previous Close
26.55 - Open
26.05 - Bid 25.70 x --
- Ask 25.60 x --
- Day's Range
25.70 - 26.40 - 52 Week Range
14.62 - 32.90 - Volume
20,005 - Avg. Volume
54,537 - Market Cap (intraday)
1.4B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
78.79 - EPS (TTM)
0.33 - Earnings Date Nov 20, 2024
- Forward Dividend & Yield 0.08 (0.31%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
27.64
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
www.celonpharma.com566
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CLN.WA
View MorePerformance Overview: CLN.WA
Trailing total returns as of 1/8/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLN.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLN.WA
View MoreValuation Measures
Market Cap
1.40B
Enterprise Value
1.31B
Trailing P/E
78.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.75
Price/Book (mrq)
2.71
Enterprise Value/Revenue
7.29
Enterprise Value/EBITDA
16.25
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.99%
Return on Assets (ttm)
-4.76%
Return on Equity (ttm)
-9.83%
Revenue (ttm)
206.81M
Net Income Avi to Common (ttm)
-45.48M
Diluted EPS (ttm)
0.33
Balance Sheet and Cash Flow
Total Cash (mrq)
121.09M
Total Debt/Equity (mrq)
3.32%
Levered Free Cash Flow (ttm)
1.08M